Publications by authors named "Raphael J Landovitz"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,621

Total Likes

662

Extended Reach

2,298,765

Social Features

318
A
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.
Rajesh T Gandhi, Raphael J Landovitz, Paul E Sax, Davey M Smith, Sandra A Springer, Huldrych F Günthard, Melanie A Thompson, Roger J Bedimo, Constance A Benson, Susan P Buchbinder

JAMA· February 2025

Videos about Article: user user

2 4 3 163 3 21

View All Article and Social Media Activity
H
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Ruanne V Barnabas, Elizabeth R Brown, Anna Bershteyn, Helen C Stankiewicz Karita, Christine Johnston, Lorna E Thorpe, Angelica Kottkamp, Kathleen M Neuzil, Miriam K Laufer, Meagan Deming

March 2021

Videos about Article: user

1 3 148 2 5 3

View All Article and Social Media Activity
S
Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083.
Hannah P Moore, Jessica M Fogel, Mark A Marzinke, Elias K Halvas, Urvi M Parikh, Raphael J Landovitz

Open Forum Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083.
Brett Hanscom, Mark A Marzinke, Xinnong Li, Deborah Donnell, Robert Bies, Raphael J Landovitz

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir pharmacokinetics in Asians with and without HIV.
Kelong Han, Ahmed A Abulfathi, Rashmi S Mehta, Romina A Nand, Mark A Marzinke, Raphael J Landovitz

Int J Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferences for HIV prevention conditional cash transfers among Black/African American and Latinx cisgender MSM in Los Angeles.
Corrina Moucheraud, Dillon Trujillo, Zachary Wagner, Wendy Garland, Terry Smith, Raphael J Landovitz

AIDS· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preexposure Prophylaxis for HIV: Updated Recommendations From the 2024 International Antiviral Society-USA Panel.
Raphael J Landovitz, Jean-Michel Molina, Susan P Buchbinder,

JAMA· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.
Todd T Brown, Robert F Arao, Maryam Warsi, Nittaya Phanuphak, Ricardo Vasconcelos, Raphael J Landovitz

Clin Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of DNA profiling to resolve HIV status in a person using injectable cabotegravir for HIV pre-exposure prophylaxis.
Jessica M Fogel, M Ali Salih, Kathy Haddaway, Mark A Marzinke, Christi Marshall, Raphael J Landovitz

J Clin Pathol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection.
Myra Happe, Rebecca M Lynch, Carl J Fichtenbaum, Sonya L Heath, Susan L Koletar, Raphael J Landovitz

JCI Insight· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084.
Jessica M Fogel, Deborah Persaud, Estelle Piwowar-Manning, Paul Richardson, Joseph Szewczyk, Raphael J Landovitz

AIDS Res Hum Retroviruses· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, Yunda Huang, Carmen A Paez, Raphael J Landovitz

Lancet HIV· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084.
Sinead Delany-Moretlwe, Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Raphael J Landovitz

J Int AIDS Soc· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on HIV Chemoprevention.
Cheríe S Blair, Mary Catherine Cambou, Raphael J Landovitz

Annu Rev Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
Raphael J Landovitz, Li Tao, Juan Yang, Melanie de Boer, Christoph Carter

Clin Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial.
Stanley E Cooper, Shuaiqi Zhang, Daniel Haines, Kenneth H Mayer, K Rivet Amico, Raphael J Landovitz

AIDS Behav· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for a randomized controlled trial with a stepped care approach, utilizing PrEP navigation with and without contingency management, for transgender women and sexual minority men with a substance use disorder: Assistance Services Knowledge-PrEP (A.S.K.-PrEP).
Cathy J Reback, Raphael J Landovitz, David Benkeser, Ali Jalali, Steven Shoptaw

Addict Sci Clin Pract· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.
Meredith E Clement, Brett Hanscom, Daniel Haines, Jose A Bazan, Nuntisa Chotirosniramit, Raphael J Landovitz

Clin Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis.
Raphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, Mark A Marzinke, Estelle Piwowar-Manning

N Engl J Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis.
Jessica M Fogel, Estelle Piwowar-Manning, Amber Moser, Tinia Hill, Shahnaz Ahmed, Raphael J Landovitz

Microbiol Spectr· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Kelong Han, Parul Patel, Scott McCallister, Alex R Rinehart, Yash Gandhi, Raphael J Landovitz

Antimicrob Agents Chemother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Christina Psaros, Georgia R Goodman, Jasper S Lee, Whitney Rice, Colleen F Kelley, Raphael J Landovitz

J Int AIDS Soc· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
Alyssa K Amick, G Ege Eskibozkurt, Sybil G Hosek, Clare F Flanagan, Raphael J Landovitz

Clin Infect Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Raphael J Landovitz, Brett S Hanscom, Meredith E Clement, Ha V Tran, Esper G Kallas

Lancet HIV· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Mark A Marzinke, Brett Hanscom, Zhe Wang, Steven A Safren, Christina Psaros, Raphael J Landovitz

Lancet HIV· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis.
Aniruddha Hazra, Raphael J Landovitz, Mark A Marzinke, Connor Quinby, Catherine Creticos

AIDS· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis